Longevity biotech is now a market. The Longevity Biotech Report 2026 tracks 3,036 assets across 781 companies and projects a $617BN annual market by 2045. Read it here: Sponsored by MuseCell Innovations: #LongevityBiotech#

Zsolt Farkas of Evolut on why today’s longevity valuations only work if the winners spend the next decade buying everything around them. #longevity# #biotech# #valuations# #M#&A #Evolut#

Oxford biotech secures $47 million to scale cell-based mRNA manufacturing, with an eye on therapies that require repeated dosing. #longevity# #biotech# #mRNA# #manufacturing# #therapies#

Chinese biotechs can run trials 50–70% faster – our report shows where that speed is paying off, and where the road narrows. #longevity# #biotech# #trials# #ChineseBiotechs# #report#